Labcorp Holdings Inc. filed an 8-K with the SEC on September 22, 2026, disclosing its response to preliminary Clinical Laboratory Fee Schedule payment rates released by CMS on September 21, 2026, and reaffirming the long-term financial outlook the company announced at its Investor Day on September 10, 2026.

Key Highlights

  • CMS rate release: The Centers for Medicare & Medicaid Services released preliminary Clinical Laboratory Fee Schedule payment rates on September 21, 2026, applicable from 2027 through 2029 under PAMA.
  • Company position: Labcorp Holdings stated it believes the rates "are based on data that is not fully representative of the broader commercial laboratory market and would impose steep annual payment cuts that threaten patient access to laboratory services."
  • Long-term outlook reaffirmed: The company reaffirmed its 2026-2029 long-term outlook, originally announced at its September 10, 2026, Investor Day, including compound annual revenue growth between 5% and 8%.
  • Margin and EPS targets: The reaffirmed outlook includes adjusted operating margin expansion between 75 and 150 basis points by the end of 2029 and compound annual adjusted EPS growth between 8.5% and 11.5%.
  • 2027 guidance timing: The company stated it expects to provide additional information on the impact of the CMS payment rates on its 2027 financial guidance when that guidance is announced in February 2027.
  • Legislative support: The company disclosed that it continues to support the bipartisan RESULTS Act as a legislative solution to PAMA reimbursement pressure.

Labcorp Holdings Responds to Preliminary Medicare Lab Payment Rates

Labcorp Holdings Inc. (NYSE:LH), a laboratory services company headquartered in Burlington, North Carolina, filed the current report under Item 7.01 (Regulation FD Disclosure) in response to CMS's September 21, 2026, release of preliminary Clinical Laboratory Fee Schedule rates. According to the filing, those rates are set under the Protecting Access to Medicare Act and would govern payments from 2027 through 2029. The company stated that it believes the data underlying the rates does not fully represent the broader commercial laboratory market and that the proposed cuts "threaten patient access to laboratory services."

The filing disclosed that Labcorp had already factored anticipated PAMA-related reimbursement pressure into the long-term outlook it presented at its September 10, 2026, Investor Day. The company stated it is now reaffirming that 2026-2029 outlook in full, which includes compound annual revenue growth between 5% and 8%, adjusted operating margin expansion between 75 and 150 basis points by the end of 2029, compound annual adjusted EPS growth between 8.5% and 11.5%, and compound annual free cash flow growth in line with adjusted earnings growth. The company also noted it continues to evaluate the CMS rates and will address their impact on 2027 financial guidance when that guidance is issued in February 2027.

The filing specified that the adjusted financial measures cited in the outlook, including adjusted EPS growth, adjusted operating margin expansion, and free cash flow, are non-GAAP measures. The company stated it is unable to provide forward-looking GAAP reconciliations for these figures without unreasonable effort, as certain components cannot be predicted. The company characterized these measures as useful supplements to, but not substitutes for, GAAP measures when evaluating operational performance.

What Was Disclosed

Labcorp Holdings filed an 8-K disclosing its view of newly released CMS Clinical Laboratory Fee Schedule rates and reaffirming the 2026-2029 long-term financial outlook first presented at its September 10, 2026, Investor Day. The company also disclosed that updated 2027 guidance incorporating CMS rate impacts will be provided in February 2027.